Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients

INTRODUCTION: Evocalcet is a recently approved calcimimetic agent for secondary hyperparathyroidism (SHPT). In this study, the efficacy and safety of once-daily oral evocalcet were evaluated in patients without prior cinacalcet use (nonusers) and previously treated patients (users). METHODS: This po...

Descripción completa

Detalles Bibliográficos
Autores principales: Koiwa, Fumihiko, Tokunaga, Shin, Asada, Shinji, Endo, Yuichi, Fukagawa, Masafumi, Akizawa, Tadao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589700/
https://www.ncbi.nlm.nih.gov/pubmed/34805635
http://dx.doi.org/10.1016/j.ekir.2021.08.020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589700/
https://www.ncbi.nlm.nih.gov/pubmed/34805635
http://dx.doi.org/10.1016/j.ekir.2021.08.020

Ejemplares similares